Merck’s Earlier Substantial Help — With China’s BioScience Oncology Darling BeiGene — Has Paid Off Handsomely

I just noticed that earlier in the week — in Guangzhou, Guangdong Province, China — BeiGene has signed a deal to build a $330 million world-class biologics manufacturing facility.

Regular readers will recall that Merck rode along, as “shotgun” — in the IPO of BeiGene, in February 2016. During the ensuing year, Merck has seen its overall percentage ownership of the company decline, as it lightened up, in an orderly fashion — even as the per share price marched pretty much steadily northward. It went out at $28.62, about thirteen months ago — and now sits at just a few pennies shy of $40. Sweet.

So — Merck still holds about 6 per cent of BeiGene — and that is a nice, solid, liquid cash trove — on tap, for other international projects as they arise. In the mean time, it is a pretty safe place to store a 40-something per cent capital gain, in just over a year. As I say, very sweet. [Off the grid this afternoon, making a pro bono federal court appearance, related to the latest ACLU efforts against Agent Orange, here.]



There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: